SpineGuard specializes in the design, development, and marketing of medical devices intended to improve the safety of spinal surgery. The group is developing DSG® digital technology for real-time surgical guidance without X-rays to improve the safety and simplify the placement of bone implants, pedicle screws, and "smart" drills. SpineGuard is extending the applications of its DSG® technology to anterior scoliosis treatment, sacroiliac joint fusion, and dental implantology.

Employees

Sector

Medical Equipment, Supplies & Distribution

Calendar

10-08 Sales and Revenue Release - Q3 2026

More about the company

Market Cap	8.53M 9.58M 7.96M 7.24M 13.65M 923M 13.73M 96.11M 37.36M 470M 35.95M 35.17M 1.51B	P/E 2024	-3.63x	P/E 2025	-3.37x
Enterprise Value	8.27M 9.28M 7.71M 7.02M 13.22M 894M 13.3M 93.13M 36.2M 456M 34.83M 34.07M 1.46B	EV / Sales 2024	2.94x	EV / Sales 2025	2.33x
Free-Float	97.13%	Yield 2024 *	-	Yield 2025	-

10-05	Weekly earnings calendar: PepsiCo kicks off the quarterly marathon
09-09	SpineGuard SA Reports Earnings Results for the Half Year Ended June 30, 2026	CI
09-09	SpineGuard says it can cover its funding needs through the second quarter of 2027
09-04	Weekly earnings calendar: Oracle vs Adobe, a battle of old hands
08-25	SpineGuard Wins US Patent for Robotic Ultrasound Technology	MT
08-24	Spineguard Obtains New U.S. Patent for Innovative Ultrasound Technology Designed to Determine Entry Point and Pedicular Drilling Trajectory	CI
08-24	SpineGuard lands a new US patent in spinal guidance
07-28	SpineGuard, Omnia Medical Obtain New US Patent for Dynamic Surgical Guidance Technology	MT
07-27	SpineGuard And Omnia Medical Obtain Notice Of Allowance For U.S. Patent Application For Innovative Application Of DSG Technology To Sacroiliac Joint Fusion	CI
07-27	SpineGuard Secures a New Patent in the United States
07-08	Spineguard SA Reports Unaudited Consolidated Revenue Results for the Second Quarter and First Half of 2026	CI
07-07	Zonebourse earnings calendar for company results: July 8, 2026
05-27	SpineGuard Secures Three Patent Applications in US	MT

09-09	SpineGuard Reports 2026 Half-Year Results	BU
08-24	SpineGuard Obtains a New U.S. Patent for Its Innovative Ultrasound Technology Designed to Determine the Entry Point and Pedicular Drilling Trajectory	BU
07-27	SpineGuard and Omnia Medical Obtain a New U.S. Patent for Their Innovative Application of DSG Technology to Sacroiliac Joint Fusion	BU
07-08	SpineGuard Announces its H1 2026 Revenue	BU
05-26	SpineGuard Obtains Three New Patents for Full Protection in the U.S. of Its Innovative Solutions Integrating DSG Technology	BU

10-04	Agenda des résultats de la semaine : PepsiCo lance le marathon trimestriel
10-02	Agenda Zonebourse des résultats de sociétés : semaine du 5 au 9 octobre 2026
09-09	SpineGuard estime pouvoir couvrir ses besoins de financement jusqu'au deuxième trimestre 2027
09-09	SpineGuard annonce ses résultats semestriels 2026
09-04	Agenda Zonebourse des résultats de sociétés : semaine du 7 au 11 septembre 2026

Manager	Title	Age	Since
Pierre Jérôme CEO	Chief Executive Officer	-	14/02/2020
Anne-Charlotte Millard DFI	Director of Finance/CFO	-	31/12/2008
Thibault Chandanson CTO	Chief Tech/Sci/R&D Officer	-	31/08/2019

SpineGuard Share Price Other OTC

Stocks

Medical Equipment, Supplies & Distribution

Valuation: SpineGuard

Latest news: SpineGuard

Analysts' recommendations: SpineGuard

Press Releases: SpineGuard

News in other languages: SpineGuard

Managers and Directors: SpineGuard

Medical Equipment

Financials

Company Profile

Director	Title	Age	Since
Stéphane Bette BRD	Director/Board Member	-	15/01/2009
Maurice Bourlion BRD	Director/Board Member	-	01/07/2009
Pierre Jérôme CHM	Chairman	-	28/02/2018

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SPINEGUARD	-.--%	-.--%	-	-	9.81M
ABBOTT LABORATORIES	+2.67%	-1.17%	-25.63%	+4.65%	169B
MEDTRONIC PLC	+1.84%	-0.76%	-9.96%	+15.34%	110B
STRYKER CORPORATION	+3.55%	+4.72%	-23.02%	+7.15%	106B
ESSILORLUXOTTICA	+1.19%	+0.42%	-48.90%	-11.41%	73.87B
CENCORA, INC.	+1.90%	+2.61%	+4.02%	+72.41%	58.98B
HOYA CORPORATION	+1.32%	+4.32%	+14.41%	+64.37%	51.28B
BECTON, DICKINSON AND COMPANY	+2.19%	-1.71%	-6.68%	-30.44%	48.16B
IDEXX LABORATORIES, INC.	+1.67%	+1.50%	-16.50%	+21.67%	40.84B
DEXCOM, INC.	+1.80%	+0.32%	+29.60%	-0.91%	32.21B
Average	+1.81%	-0.86%	-9.18%	+15.87%	76.69B
Weighted average by Cap.	+2.21%	-1.30%	-15.26%	+13.55%

	2024	2025
Net sales	4.65M 5.22M 4.33M 3.94M 7.43M 502M 7.48M 52.34M 20.35M 256M 19.58M 19.15M 823M	3.76M 4.22M 3.5M 3.19M 6.01M 406M 6.05M 42.31M 16.45M 207M 15.83M 15.48M 666M
Net income	-3.08M -3.46M -2.87M -2.61M -4.93M -333M -4.96M -34.71M -13.49M -170M -12.98M -12.7M -546M	-2.07M -2.32M -1.93M -1.75M -3.31M -223M -3.33M -23.28M -9.05M -114M -8.71M -8.52M -366M
Net Debt	1.82M 2.04M 1.7M 1.54M 2.91M 197M 2.93M 20.48M 7.96M 100M 7.66M 7.49M 322M	-265K -298K -247K -225K -424K -28.68M -427K -2.99M -1.16M -14.63M -1.12M -1.09M -47.01M